Anne D Pham, Author at ALS Finding a Cure®

Biomarker Studies to Accelerate Diagnosis and Identify Therapeutic Targets Northeast ALS Consortium (NEALS) Biorepository Infrastructure Improvement and Expansion Protocol

Anne D Pham2021-06-17T14:55:01+00:00

Biomarker Studies to Accelerate Diagnosis and Identify Therapeutic Targets Northeast ALS Consortium (NEALS) Biorepository Infrastructure Improvement and Expansion Protocol Research Summary Principle Investigators: James Berry MD, Nazem Atassi MD & Merit Cudkowicz MD The exact cause of amyotrophic lateral sclerosis remains unknown, and there are no tests to diagnose the disease or follow its progression. Such tests, known as biomarkers, would be invaluable to speed the development of novel therapies for ALS. In recent years, ALS scientists have begun to identify promising potential biomarkers in the blood and spinal fluid of people with the disease. The next step to build [...]

Biomarker Studies to Accelerate Diagnosis and Identify Therapeutic Targets Northeast ALS Consortium (NEALS) Biorepository Infrastructure Improvement and Expansion ProtocolAnne D Pham2021-06-17T14:55:01+00:00

TRACK-ALS: Imaging and Biofluid Biomarkers in Amyotrophic Lateral Sclerosis

Anne D Pham2021-06-17T14:51:22+00:00

TRACK-ALS: Imaging and Biofluid Biomarkers in Amyotrophic Lateral Sclerosis Research Summary Principle Investigators: Nazem Atassi MD, Joseph Masdeu MD, PHD & A. Nadeem Ishaque PhD This is a very exciting collaborative project among industry, academia and the ALS Association (ALSA). The overall goal of this project is to identify new imaging markers of ALS that can be used to accelerate ALS diagnostic timelines and the pace of ALS drug development. We plan to compare innovative MRI signals between 50 people with ALS and 50 healthy volunteers, and to study these MRI signals over time in relationship with ALS clinical presentation, [...]

TRACK-ALS: Imaging and Biofluid Biomarkers in Amyotrophic Lateral SclerosisAnne D Pham2021-06-17T14:51:22+00:00

A loved one’s diagnosis moved this UCLA Health researcher to take on ALS
Gallery

A loved one’s diagnosis moved this UCLA Health researcher to take on ALS

Anne D Pham2022-04-06T14:40:49+00:00

A loved one’s diagnosis moved this UCLA Health researcher to take on ALS Computational geneticist developed a blood test that could detect how fast muscle cells are dying, potentially aiding diagnosis. After a parent is diagnosed with an incurable disease, it’s natural to feel an urge to do anything possible to help. For some people, that could be advocacy, or household assistance, or tracking down the best available medical care. For Noah Zaitlen, Phd, associate professor of computational medicine and neurology at UCLA Health, it meant launching a research project to create a better diagnostic test for a debilitating neurological [...]

A loved one’s diagnosis moved this UCLA Health researcher to take on ALSAnne D Pham2022-04-06T14:40:49+00:00

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial
Gallery

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial

Anne D Pham2021-09-07T16:20:38+00:00

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial Coya Therapeutics has raised $10 million in funding to advance the development of ALS001, a potential regulatory T-cell (Treg) therapy aiming to halt amyotrophic lateral sclerosis (ALS) progression, now in a Phase 2 study in patients. Proceeds raised in this series A funding round will also be used to introduce into testing similar treatments for other neurodegenerative disorders. “Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg cell therapy shows great potential in unlocking a new treatment paradigm [...]

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS TrialAnne D Pham2021-09-07T16:20:38+00:00

Answer ALS Launches ‘The Data is Here’ Campaign to Announce the Release of the World’s Largest Open Sourced ALS Data Portal
Gallery

Answer ALS Launches ‘The Data is Here’ Campaign to Announce the Release of the World’s Largest Open Sourced ALS Data Portal

Anne D Pham2021-09-07T16:20:38+00:00

Answer ALS Launches 'The Data is Here' Campaign to Announce the Release of the World's Largest Open Sourced ALS Data Portal The Answer ALS Data Portal seeks to empower researchers around the globe with the data needed to finally answer ALS NEW ORLEANS, Jan. 8, 2021 /PRNewswire/ -- Answer ALS, in cooperation with the Stephen Hawking Foundation, launches "The Data is Here" campaign on January 8 and on what would have been the famed Theoretical Physicist's 79th birthday. The campaign features a video tribute to Stephen Hawking and his tireless efforts to solve complex universal questions, while living with ALS for over 50 years. [...]

Answer ALS Launches ‘The Data is Here’ Campaign to Announce the Release of the World’s Largest Open Sourced ALS Data PortalAnne D Pham2021-09-07T16:20:38+00:00

Multi-center, multi-tracer PET studies harmonized to detect neuroinflammation in ALS

Anne D Pham2021-09-07T16:21:02+00:00

Multi-center, multi-tracer PET studies harmonized to detect neuroinflammation in ALS Reston, VA--A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease. Pooling data acquired from different scanners, different neuroinflammation positron emission tomography (PET) markers and different sites enhanced researchers' ability to detect neuroinflammation in ALS patients. This research was published in the November issue of The Journal of Nuclear Medicine. ALS is a rare and fatal neurodegenerative disease that causes progressive weakness, respiratory failure and eventual death. Developing drugs to treat the disease [...]

Multi-center, multi-tracer PET studies harmonized to detect neuroinflammation in ALSAnne D Pham2021-09-07T16:21:02+00:00

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Anne D Pham2021-09-07T16:21:02+00:00

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the first subject has been enrolled in the Phase 2a clinical trial evaluating AT-1501, the Company’s lead product candidate, in adults with amyotrophic lateral sclerosis (ALS). AT-1501 blocks the activation of the CD40L pathway, which has been shown to improve muscle function, slow [...]

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral SclerosisAnne D Pham2021-09-07T16:21:02+00:00

Aural Analytics To Power Speech-Based Endpoints For The Healey Center ALS Platform Trial at Mass General Hospital

Anne D Pham2021-09-07T16:21:03+00:00

Aural Analytics To Power Speech-Based Endpoints For The Healey Center ALS Platform Trial at Mass General Hospital The first-ever platform trial for ALS is set to kick off this month and is led by investigators at the Sean M. Healey & AMG Center for ALS at Mass General Hospital Aural Analytics’ award-winning clinical trials platform will provide speech collection and speech-based digital endpoints for the HEALEY ALS Platform trial study regimens August 06, 2020 02:03 PM Eastern Daylight Time SCOTTSDALE, Ariz. & BOSTON--(BUSINESS WIRE)--Aural Analytics, Inc., a privately held digital health company developing the world’s most advanced suite of clinical-grade [...]

Aural Analytics To Power Speech-Based Endpoints For The Healey Center ALS Platform Trial at Mass General HospitalAnne D Pham2021-09-07T16:21:03+00:00

ALS Drug Works in Study, Researchers Say

Anne D Pham2021-09-07T16:21:24+00:00

An experimental drug slowed the paralyzing march of amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in a clinical trial, according to researchers who say the results are a fresh sign that recent insights into the condition may soon bring new medicines.

ALS Drug Works in Study, Researchers SayAnne D Pham2021-09-07T16:21:24+00:00

The ALS Association, ALS Finding A Cure, and MDA Co-Fund Clinical Trial Grant to Study Restoring Immune System Function to Treat ALS

Anne D Pham2021-09-07T16:21:24+00:00

The ALS Association, ALS Finding A Cure, and MDA Co-Fund Clinical Trial Grant to Study Restoring Immune System Function to Treat ALS The ALS Association, ALS Finding a Cure (ALSFAC), and MDA announced they have jointly awarded a clinical trial grant totaling more than $2.5 million over two-and-a-half years to leading investigators at the Houston Methodist Neurological Institute and Massachusetts General Hospital. The principal investigator is Stanley Appel, MD, co-director of Houston Methodist Neurological Institute, chair of the Stanley H. Appel Department of Neurology and the Peggy and Gary Edwards Distinguished Chair in ALS at Houston Methodist Hospital, and professor [...]

The ALS Association, ALS Finding A Cure, and MDA Co-Fund Clinical Trial Grant to Study Restoring Immune System Function to Treat ALSAnne D Pham2021-09-07T16:21:24+00:00

About Anne D Pham